암 조직 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Tissue Diagnostics Market size is expected to reach USD 25.11 Billion in 2034 from USD 16.20 Billion (2025) growing at a CAGR of 4.99% during 2026-2034.

The global cancer tissue diagnostics market is expanding rapidly due to the growing need for accurate cancer diagnosis and personalized treatment planning. Tissue diagnostics involve the examination of biopsy samples using techniques such as immunohistochemistry, in situ hybridization, and molecular testing. These methods help physicians identify cancer types, determine disease progression, and select appropriate therapies.

The rising global burden of cancer and increasing emphasis on early detection are key drivers of market growth. Advanced diagnostic technologies are improving the precision and speed of cancer detection, enabling better treatment decisions. Healthcare institutions are also investing in modern pathology laboratories equipped with automated diagnostic systems.

In the future, the cancer tissue diagnostics market is expected to benefit from advancements in molecular diagnostics and precision medicine. Integration of digital pathology, artificial intelligence, and genomic testing will further enhance diagnostic capabilities. As cancer research continues to evolve, tissue diagnostics will remain a critical component of effective cancer management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Kit Type

• In Situ Hybridization (ISH) Test Kits
• Molecular Diagnostics Test Kits
• Companion Diagnostics Test Kits
• Immunohistochemistry (IHC) Test Kits

By Cancer

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Ovarian Cancer
• Hematologic Cancer
• Liver Cancer
• Pancreatic Cancer
• Skin Cancer (Melanoma)
• Others

By End-user

• Hospitals
• Specialty Centers
• Long-term Care Centers
• Diagnostic Centers
• Academic & Research Institutes

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Quest Diagnostics Incorporated, Agilent Technologies Inc, Illumina Inc, BioRad Laboratories Inc, QIAGEN NV, Takara Bio Inc, Enzo Life Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET: BY TEST KIT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Test Kit Type
• 4.2. In Situ Hybridization (ISH) Test Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Molecular Diagnostics Test Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Companion Diagnostics Test Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunohistochemistry (IHC) Test Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET: BY CANCER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Cancer
• 5.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Hematologic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Skin Cancer (Melanoma) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Long-term Care Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER TISSUE DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Test Kit Type
  • 7.2.2 By Cancer
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Test Kit Type
  • 7.3.2 By Cancer
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Test Kit Type
  • 7.4.2 By Cancer
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Test Kit Type
  • 7.5.2 By Cancer
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Test Kit Type
  • 7.6.2 By Cancer
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER TISSUE DIAGNOSTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 Abbott Laboratories
  • 9.2.4 Danaher Corporation
  • 9.2.5 Merck KGaA
  • 9.2.6 Quest Diagnostics Incorporated
  • 9.2.7 Agilent Technologies Inc
  • 9.2.8 Illumina Inc
  • 9.2.9 Bio-Rad Laboratories Inc
  • 9.2.10 QIAGEN N.V
  • 9.2.11 Takara Bio Inc
  • 9.2.12 Enzo Life Sciences Inc